A case of autoimmune pulmonary alveolar proteinosis with severe respiratory failure treated with segmental lung lavage and oral statin therapy. (2022)

• Record Type: Journal Article
• Authors: Takano, Tomotsugu; Takeda, Keisuke; Nakamura, Satoshi; Akiyama, Genta; Ando, Nobuhisa; Komori, Masashi
• Is Part Of: Respiratory medicine case reports. Volume 38(2022)
• Publication Date: 2022
• Subjects: Pulmonary alveolar proteinosis -- Granulocyte-macrophage colony-stimulating factor -- Dyslipidemia -- Whole lung lavage -- Segmental lung lavage -- Non-invasive cholesterol treatment; BAL bronchoalveolar lavage -- CT computed tomography -- ECMO extracorporeal membrane oxygenation -- GM-CSF granulocyte-macrophage colony-stimulating factor -- HOT home oxygen therapy -- PAP pulmonary alveolar proteinosis -- SLL segmental lung lavage -- WLL whole-lung lavage; Respiratory organs -- Diseases -- Periodicals; Chest -- Diseases -- Periodicals; Respiratory Tract Diseases -- Periodicals; Respiratory System -- Periodicals; Chest -- Diseases; Respiratory organs -- Diseases; Electronic journals; Periodicals; 616.2
• DOI: 10.1016/j.rmcr.2022.101684
• Languages: English
• ISSNs: 2213-0071

Abstract

Abstract: Pulmonary alveolar proteinosis (PAP) is a diffuse lung disease characterized by the accumulation of alveolar surfactants due to dysfunction of granulocyte-macrophage colony-stimulating factor-dependent cholesterol clearance. Whole-lung lavage is the current standard of care for PAP, but it can lead to the exacerbation of hypoxia. A medication targeting cholesterol homeostasis is a promising therapy for refractory PAP. We present a case of autoimmune PAP with severe hypoxia that was successfully treated with segmental lung lavage (SLL). Following SLL for disease relapse, statin treatment for dyslipidemia was started. After initiating statin treatment, the patient did not require bronchoalveolar lavage for 10 months.